Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 4:10:1144.
doi: 10.3389/fonc.2020.01144. eCollection 2020.

Recurrence/Regrowth in Grade I Meningioma: How to Predict?

Gervásio Teles Cardoso de Carvalho  1   2   3 , Warley Carvalho da Silva-Martins  4 , Kênia Cristina Soares Fonseca de Magalhães  1 , Cristiana Buzelin Nunes  5   6 , Aleida Nazareth Soares  1 , Luciene Simões de Assis Tafuri  1   7 , Renata Toscano Simões  1
Affiliations

Recurrence/Regrowth in Grade I Meningioma: How to Predict?

Gervásio Teles Cardoso de Carvalho et al. Front Oncol. .

Abstract

The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth (p = 0.486), but was significantly correlated with peritumoral edema (p = 0.031) and intratumoral calcifications (p = 0.018). Recurrent meningiomas were observed in 14.6% of cases. Immunostaining for each marker was: HLA-G 100%; HLA-E 95.6%; PR 62%; ER 2.1%; AR 6.5%; p53 92.6%; COX-2 100%; HER2 0%; Ki67, mean 2.61 ± 2.29%, median 2.1%. Primary and recurrent meningiomas showed no significant relation with HLA-E and hormone receptors (p > 0.05), except for Ki67, where a higher median was observed in recurrent tumors than in primary (p = 0.014). The larger the tumor, the more severe the peritumoral edema, and the greater the presence of calcifications. Ki67 appears to be a good biomarker of recurrence/regrowth in grade I meningiomas.

Keywords: HLA-E; HLA-G; MIB-1; hormonal receptors; immunomarkers; inflammatory biomarkers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival curve for patients who undergo surgical treatment of meningioma.
Figure 2
Figure 2
Free recurrence/regrowth survival for patients who undergo surgical treatment of meningioma.
Figure 3
Figure 3
The survival curve by the Kaplan-Meier method compared by the Log-Rank test concerning to Simpson's tumor resection degrees for patients who undergo surgical treatment of meningioma.
Figure 4
Figure 4
The survival curve by the Kaplan-Meier method compared by the Log-Rank test concerning to tumor size for patients who undergo surgical treatment of meningioma.
Figure 5
Figure 5
The survival curve by the Kaplan-Meier method compared by the Log-Rank test concerning to cut-off for Ki67 for patients who undergo surgical treatment of meningioma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bhat AR, Wani MA, Kirmani AR, Ramzan AU. Histological-subtypes and anatomical location correlated in meningeal brain tumors (meningiomas). J Neurosci Rural Pract. (2014) 5:244–9. 10.4103/0976-3147.133568 - DOI - PMC - PubMed
    1. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. (2017) 19:v1–88. 10.1093/neuonc/nox158 - DOI - PMC - PubMed
    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. . The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. (2016) 131:803–20. 10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Telugu R, Chowhan A, Rukmangadha N, Patnayak R, Phaneendra B, Prasad B, et al. . Human epidermal growth factor receptor 2/neu protein expression in meningiomas: an immunohistochemical study. J Neurosci Rural Pract. (2016) 7:526–31. 10.4103/0976-3147.188640 - DOI - PMC - PubMed
    1. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. “Malignancy” in meningiomas: A clinicopathologic study of 116 patients, with grading implications. Cancer. (1999) 85:2046–56. 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M - DOI - PubMed